Abstract:Despite the current multimodal approach to treatment of anaplastic thyroid cancer (ATC), the prognosis for patients with the disease is poor. New effective therapy for ATC is desperately needed. Thus, we investigated the effects of manumycin (a farnesyl:protein transferase inhibitor), alone and in combination with other drugs frequently used to treat ATC, in six human ATC cell lines: ARO, C643, DRO, Hth-74, KAT-4, and KAT-18. By means of a formazan dye-based spectrophotometric assay of cell viability and light microscopy, manumycin was shown to decrease the number of viable cells in all six of the cell lines though to a lesser degree in DRO and C643 cells than in ARO, Hth-74, KAT-4, and KAT-18 cells, In combination, manumycin enhanced the effect of paclitaxel in all six of the cell Lines. The mechanism of cell death was investigated by measuring caspase-3 activity, immunoblotting with anti-poly-(ADP-ribose)polymerase (PARP) antibody and electrophoresis of DNA. After an 18-h incubation, manumycin plus paclitaxel caused enhanced activation of caspase-3 activity, cleavage of PARP into M(r)89,000 and 28,000 fragments, and internucleosomal fragmentation of DNA tall of which are characteristic of apoptotic cell death). In contrast, neither manumycin alone, paclitaxel alone, doxorubicin alone, nor doxorubicin plus manumycin produced significant specific cleavage of PARP and internucleosomal DNA fragmentation after 18 h of incubation. The in vivo effect and toxicity of combined manumycin and paclitaxel treatments were evaluated in a nude mouse xenograft model using ARO and KAT-4 cells. Drugs were injected i.p. on days 1 and 3 of a 7-day cycle for three cycles. Both manumycin (7.5 mg/kg/dose) and paclitaxel (20 mg/kg/dose) had significant inhibitory effects on tumor growth. Combined manumycin and paclitaxel treatments seemed as effective as manumycin against ARO cells and more effective than either manumycin or paclitaxel alone against KAT-I cells. No significant morbidity or mortality was caused by the treatments. In conclusion, manumycin can inhibit the growth of ATC both in vitro and in vivo. Manumycin plus paclitaxel has enhanced cytotoxic effects and increased apoptotic cell death in ATC cells in vitro compared with either drug by itself, The combination of manumycin and paclitaxel is also effective in vivo with no significant toxicity observed. The lack of synergy observed in this in vivo experiment may be due to a ceiling effect, and further experimentation is warranted to ascertain the optimal way to combine these two agents for maximal therapeutic effects.

P21 Waf-1 (Cip-1) Enhances Apoptosis Induced by Manumycin and Paclitaxel in Anaplastic Thyroid Cancer Cells.

Manumycin Enhances The Cytotoxic Effect Of Paclitaxel On Anaplastic Thyroid Carcinoma Cells

Cytochrome C Release is Upstream to Activation of Caspase-9, Caspase-8, and Caspase-3 in the Enhanced Apoptosis of Anaplastic Thyroid Cancer Cells Induced by Manumycin and Paclitaxel.

Bcl-2-associated X Protein is the Main Mediator of Manumycin A-Induced Apoptosis in Anaplastic Thyroid Cancer Cells.

Angiogenesis Inhibition in the in Vivo Antineoplastic Effect of Manumycin and Paclitaxel Against Anaplastic Thyroid Carcinoma.

Reduced Expression of P53 and P21(Waf1/Cip1) Sensitizes Human Breast Cancer Cells to Paclitaxel and Its Combination with 5-Fluorouracil

Modulation of Parathyroid Hormone-Related Protein Levels (pthrp) in Anaplastic Thyroid Cancer

Manumycin Induces Apoptosis in Human Hepatocellular Carcinoma HepG2 Cells

Redox Control Of Manumycin A-Induced Apoptosis In Anaplastic Thyroid Cancer Cells - Involvement Of The Xenobiotic Apoptotic Pathway

P53-Dependent Apoptosis is Essential for the Antitumor Effect of Paclitaxel Response to DNA Damage in Papillary Thyroid Carcinoma.

AdIκBα transfer reverses the chemoresistance to taxol by inducing apoptosis in nude mice with human non-small cell lung cancer

P2.03a-059 LCL161 Increases Paclitaxel-Induced Apoptosis by Degrading Ciap1 and Ciap2 in NSCLC: Topic: Clinical Trials

LCL161 increases paclitaxel-induced apoptosis by degrading cIAP1 and cIAP2 in NSCLC

Sequence-Dependent Potentiation of Paclitaxel-Mediated Apoptosis in Human Leukemia Cells by Inhibitors of the Mitogen-Activated Protein Kinase Kinase/Mitogen-Activated Protein Kinase Pathway

Upregulation of p21WAF1/CIP1 in human breast cancer cell lines MCF-7 and MDA-MB-468 undergoing apoptosis induced by natural product anticancer drugs 10-hydroxycamptothecin and camptothecin through p53-dependent and independent pathways.

Activation of the Mitochondria-Driven Pathway of Apoptosis in Human PC-3 Prostate Cancer Cells by a Novel Hydrophilic Paclitaxel Derivative, 7-Xylosyl-10-deacetylpaclitaxel.

Apoptosis Induced By Low-Dose Paclitaxel Is Associated With P53 Upregulation In Nasopharyngeal Carcinoma Cells

c-ABL tyrosine kinase modulates p53-dependent p21 induction and ensuing cell fate decision in response to DNA damage

Nuclear Factor-Kappab/ikappab Signaling Pathway May Contribute to the Mediation of Paclitaxel-Induced Apoptosis in Solid Tumor Cells.

Synergistic Effects of Apigenin and Paclitaxel on Apoptosis of Cancer Cells.

IMPA2 blocks cervical cancer cell apoptosis and induces PTX resistance through p53-mediated AIFM2 regulation